A carregar...
(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. (177)Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5630396/ https://ncbi.nlm.nih.gov/pubmed/29029496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19805 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|